Source: American Heart Journal. Unidade: FMRP
Subjects: DOENÇAS CARDIOVASCULARES, MORBIDADE, MORTALIDADE
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
SCHWARTZ, Gregory G. et al. Rationale and design of the sal-Outcommes trial: efficacy and safety of dalcetrapib in patients with recent acute coronary syndrome. American Heart Journal, v. 158, n. 6, p. 896-901.e3, 2009Tradução . . Acesso em: 22 dez. 2024.APA
Schwartz, G. G., Olsson, A. G., Ballantyne, C. M., Barter, P. J., Holme, I. M., Kallend, D., et al. (2009). Rationale and design of the sal-Outcommes trial: efficacy and safety of dalcetrapib in patients with recent acute coronary syndrome. American Heart Journal, 158( 6), 896-901.e3.NLM
Schwartz GG, Olsson AG, Ballantyne CM, Barter PJ, Holme IM, Kallend D, Leiter LA, Leitersdorf E, McMurray JJV, Shah PK, Tardif J-C, Chaitman BR, Maddux RD, Mathieson J, Haddad A. Rationale and design of the sal-Outcommes trial: efficacy and safety of dalcetrapib in patients with recent acute coronary syndrome. American Heart Journal. 2009 ; 158( 6): 896-901.e3.[citado 2024 dez. 22 ]Vancouver
Schwartz GG, Olsson AG, Ballantyne CM, Barter PJ, Holme IM, Kallend D, Leiter LA, Leitersdorf E, McMurray JJV, Shah PK, Tardif J-C, Chaitman BR, Maddux RD, Mathieson J, Haddad A. Rationale and design of the sal-Outcommes trial: efficacy and safety of dalcetrapib in patients with recent acute coronary syndrome. American Heart Journal. 2009 ; 158( 6): 896-901.e3.[citado 2024 dez. 22 ]
